ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Limited received a rectification order dropping an earlier income tax demand of Rs. 161.92 Crore. The demand was reduced to nil.
Solara Active Pharma Sciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This is a periodic regulatory compliance disclosure.
Solara Active Pharma Sciences Limited has issued the notice for its Ninth Annual General Meeting, scheduled to be held on September 18, 2026.
Solara Active Pharma Sciences approved the conversion of 2,79,582 partly paid-up rights shares into fully paid-up equity. The conversion followed receipt of pending first and final call monies.
Solara Active Pharma Sciences Limited allotted 2,250 equity shares under its ESOP scheme. This allotment slightly increases the company's paid-up share capital to Rs. 48.06 Crore.
Solara Active Pharma Sciences Limited allotted 2,250 equity shares following ESOP exercises. The allotment increases the company's paid-up share capital slightly to Rs. 48.06 Crore.
Solara Active Pharma Sciences revised the appointment date for Mr. Ajit Manocha as Chief Information Officer and Senior Management Personnel to August 17, 2026.
Solara achieved record EBITDA/PAT despite significant geopolitical headwinds in West Asia impacting raw material costs.
Solara Active Pharma Sciences allotted 2,250 equity shares under its ESOP scheme. This allotment marginally increases the company's paid-up share capital.
Solara Active Pharma Sciences allotted 2,250 equity shares under its 2018 ESOP scheme. This exercise realized Rs. 8.44 Lakh in capital for the company.
Solara Active Pharma Sciences appointed Mr. Ajit Manocha as Chief Information Officer. He is designated as Senior Management Personnel effective August 10, 2026.
Solara reported Q1'27 overall revenues of ₹384.3 Crore and PAT of ₹16.3 Crore. Base business revenues grew 24% YoY to ₹307.7 Crore.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹381.6 Cr (+19.6% YoY) and net profit of ₹16.3 Cr (+55.2% YoY) for Q1 FY27.
The company filed its quarterly shareholding pattern under Regulation 31. This routine regulatory disclosure details shareholding distribution across various investor categories.
Solara Active Pharma Sciences scheduled a board meeting on July 23, 2026. The board will consider unaudited standalone and consolidated financial results for Q1 FY27.
Solara Pharma issued a final reminder for unpaid call money on rights shares. Failure to pay by July 27, 2026, will lead to forfeiture of those shares.
Solara Active Pharma Sciences allotted 70,000 equity shares under its ESOP Plan 2024, raising Rs. 2.63 Crore. This increases the paid-up capital and reflects employee stock option exercises.
Solara Active Pharma Sciences allotted 2,250 equity shares under its ESOP 2018, realizing Rs. 0.08 Crore. This is a routine employee benefit exercise with minimal dilution impact.
Solara Active Pharma clarified that recent trading volume spurts are not due to undisclosed material events. The company remains compliant with all SEBI disclosure regulations.
Solara Active Pharma submitted its Annual Secretarial Compliance Report for FY 2025-26. The auditor confirmed zero material non-compliances, ensuring robust governance standards.
Solara delivered its highest Q4 revenue in 8 quarters at INR 392cr, driven by a strong base business with 54% gross margins, despite persistent headwinds and negative EBITDA in the Ibuprofen segment.
Solara's base business shows strong momentum, hitting eight-quarter highs in revenue and EBITDA, yet the Ibuprofen segment remains a significant drag, forcing a strategic review and potential divestment of the vertical.
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹387.3 Cr (+41.9% YoY) and net profit of ₹9.6 Cr for Q4 FY26.
Solara Active Pharma Sciences scheduled a board meeting for May 15, 2026, to approve audited financial results. The trading window remains closed until May 17.
Solara Active Pharma Sciences announced the successful closure of a US FDA inspection at its Puducherry Ibuprofen facility. The inspection, conducted in February 2026, concluded with a 'Voluntary Action Indicated' classification and issuance of an Establishment Inspection Report. The site remains in a state of cGMP compliance, supporting its global API manufacturing strategy.
Solara Active Pharma Sciences Limited has issued a final call notice for ₹134.99 Crore (₹112.50 per share) to holders of partly paid-up rights equity shares. The payment period runs from April 23 to May 07, 2026. Failure to pay will result in the forfeiture of shares and previously paid amounts.